Orange bets on AI for network optimization, automation
Artefact mentioned in this interview from Brelotte Ba, deputy CEO of Orange Middle East and Africa, by Connecting Africa, on Orange's latest AI and GenAI projects.
Compound AI Systems: The Future of Specialized Intelligence
Since its explosive emergence in mid-2022, generative AI has quickly captured global attention. What initially centered on the language modality has since expanded into exciting new avenues, including image, audio, and video models. Early in 2023, speculation about the technology's potential impact on businesses across various industries grew, accompanied by exciting early adoption cases. As more developers began building solutions with these models, the general perception shifted toward the continuous emergence of newer, larger, and hopefully better versions of the most widely used models.
Is GenAI hype dying? – Why now is the best time to build
Generative AI is a game-changer with applications across industries. Companies are actively discussing it, venture capitalists are heavily investing, and both employees and users are captivated, making it a focal point of attention. On one side, there are optimists who believe GenAI will be as revolutionary as the internet, while on the other, pessimists argue that it’s “just another fad” with no tangible value. Pragmatists are beginning to question whether the GenAI hype is fading. This piece aims to explore these perspectives.
Is Preference Alignment Always the Best Option to Enhance LLM-Based Translation? An Empirical Analysis
Neural metrics for machine translation (MT) evaluation have become increasingly prominent due to their superior correlation with human judgments compared to traditional lexical metrics
Unleashing the power of AI in Clinical Trials: Key Insights from PFIZER and ARTEFACT – AI for Health Summit
The discussion revolved around the transformative role of AI in clinical trials, supported by insights from Pfizer and Artefact, and highlighted in their collaborative white paper. It showcased concrete use cases, ecosystem mapping, and challenges to scaling AI innovations.
SANOFI, AWS, IKTOS, ELAIA and MIND GROUP at AI for Health – The generative AI revolution for drug discovery
This roundtable explored the transformative role of GenAI in drug discovery, highlighting its potential to optimize processes, accelerate timelines, and foster collaboration in the pharmaceutical industry.
ROCHE, PULSELIFE and SALESFORCE at the AI for Health Summit – Omni-channel engagement of HCPs in the Age of GenAI
The roundtable focused on the transformative potential of AI and (GenAI) in omni-channel engagement for healthcare professionals (HCPs). The discussion explored how AI reshapes interactions, drives personalized experiences, and enhances processes across clinical trials, marketing, and patient engagement.
PFIZER at the AI for Health Summit – AI: On a mission to make drug development faster and smarter
Pfizer is leveraging AI to revolutionize drug development. AI is viewed as a game-changer, impacting every stage of the pharmaceutical process, from preclinical research to patient access and manufacturing, with both operational and transformative applications.
Leaders’ POV: Accelerating drug innovation through AI at SERVIER – AI for Health Summit
Servier has approached AI adoption in two phases. Initially, an opportunistic approach focused on proving AI's potential through specific use cases, especially in collaboration with R&D teams.
